| Patent application number | Description | Published |
|---|
| 20080222741 | Expression Profile Of Prostate Cancer - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications. | 09-11-2008 |
| 20080280771 | Protein MicroarraySystem - The present invention relates to automated methods, systems, and apparatuses for protein separation and analysis. In particular, the present invention provides an automated system for the separation, identification, and characterization of the phosphorylation status of protein samples, including the generation and analysis of protein microarrays. | 11-13-2008 |
| 20090012031 | EZH2 Cancer Markers - The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target EZH2 expression in prostate cancer. | 01-08-2009 |
| 20090047269 | METABOLOMIC CANCER TARGETS - The present invention relates to cancer markers. In particular, the present invention provides metabolites that are differentially present in prostate cancer and methods of inhibiting the growth of a cell by altering the level of such metabolites. | 02-19-2009 |
| 20090075284 | METABOLOMIC PROFILING OF PROSTATE CANCER - The present invention relates to cancer markers. In particular, the present invention provides metabolites that are differentially present in prostate cancer. | 03-19-2009 |
| 20090075833 | ADRB2 CANCER MARKERS - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ADRB2 markers for cancer. | 03-19-2009 |
| 20090104120 | DLX1 CANCER MARKERS - This invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, this invention relates to DLX1 cancer markers that are useful as diagnostic markers and clinical targets for prostate cancer. | 04-23-2009 |
| 20090208937 | Recurrent gene fusions in prostate cancer - Recurrent gene fusions in prostate cancer of androgen regulated genes or housekeeping genes and ETS family member genes are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 08-20-2009 |
| 20090239221 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions in prostate cancer of androgen regulated genes or housekeeping genes and ETS family member genes are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 09-24-2009 |
| 20100055688 | SLIT2 CANCER MARKERS - This invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, this invention relates to SLIT2 cancer markers that are useful as diagnostic markers and clinical targets for prostate cancer. | 03-04-2010 |
| 20100129804 | SPINK1 AS A PROSTATE CANCER MARKER AND USES THEREOF - Compositions and methods for cancer research, diagnosis, and treatment, including but not limited to, cancer markers are provided. In particular, SPINK1 and other markers for prostate cancer are provided. | 05-27-2010 |
| 20100222420 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 - The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target EZH2 expression in prostate cancer. | 09-02-2010 |
| 20100227910 | GENE FUSION TARGETED THERAPY - The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to recurrent gene fusions as clinical targets for prostate cancer. | 09-09-2010 |
| 20100297657 | EXPRESSION PROFILE OF PROSTATE CANCER - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications. | 11-25-2010 |
| 20110028336 | MIPOL1-ETV1 GENE REARRANGEMENTS - Compositions and methods associated with recurrent MIPOL1-ETV1 genetic rearrangements that are useful for cancer diagnosis and therapy are disclosed. | 02-03-2011 |
| 20110065113 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for prostate cancer. | 03-17-2011 |
| 20110104680 | RECURRENT GENE FUSIONS IN LUNG CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for lung cancer. | 05-05-2011 |
| 20110151497 | METABOLOMIC PROFILING OF PROSTATE CANCER - The present invention relates to cancer markers. In particular, the present invention provides metabolites and panels of metabolites that are differentially present in cancer (e.g., prostate or breast cancer). | 06-23-2011 |
